Azole resistance in Aspergillus fumigatus: A growing public health concern

Current Opinion in Infectious Diseases

Volumn 26, Issue 6, 2013, Pages 493-500

  Vermeulen, Edith ^a   Lagrou, Katrien ^a,b   Verweij, Paul E ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

aspergillosis; Aspergillus fumigatus; CYP51A; drug resistance; fungal

Indexed keywords

PYRROLE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ASPERGILLUS FUMIGATUS; CHINA; CYP51A GENE; EPIDEMIOLOGICAL DATA; EUROPE; FUNGAL STRAIN; GENOTYPE; HIGH RISK PATIENT; HUMAN; INDIA; IRAN; MIDDLE EAST; NETHERLANDS; NONHUMAN; PUBLIC HEALTH PROBLEM; REVIEW; TANDEM REPEAT;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; DRUG RESISTANCE, MULTIPLE, FUNGAL; FUNGAL PROTEINS; HUMANS;

EID: 84887317220     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000005     Document Type: Review

References (54)

1. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B: acquired resistance to itraconazole. Scand J Infect Dis 1997; 29:509-512.
2. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41:1364-1368.
3. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 2001; 39:2431-2438.
4. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356:1481-1483.
5. Mellado E, Garcia-Effron G, Alcá zar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of CYP51A alterations. Antimicrob Agents Chemother 2007; 51:1897-1904.
6. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15:1068-1076.
7. Verweij PE, Snelders E, Kema GH, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009; 9:789-795.
8. Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65:2116-2118.
9. Lagrou K, De Vleeschouwer J, Meersseman W, et al. Triazole resistance among clinical Aspergillus fumigatus isolates. 3rd Advances Against Aspergillosis Congress; 16-19 January 2008; Miami Beach, Florida; poster
10. Mortensen KL, Jensen RH, Johansen HK, et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratorybased study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011; 49:2243-2251.
11. Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azoleresistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2012; 56:869-874.
12. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5:e219.
13. van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011; 17:1846-1854.
14. van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates fromdomiciles. Clin Infect Dis 2013; 57 (4):513-520
15. Alastruey-Izquierdo A, Mellado E, Peláez T, et al., FILPOP Study Group. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 2013; 57:3380-3387.
16. Escribano P, Pelá ez T, Mun oz P, et al Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother 2013; 57 2815-2820. This article is one of the few epidemiological studies that give resistance data for patients with relevant aspergillus disease, instead of data for clinical isolates irrespective of relevance.
17. Alanio A, Sitterlé E, Liance M, et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66:371-374.
18. Morio F, Aubin GG, Danner-Boucher I, et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 2012; 67:1870-1873.
19. Bader O, Weig M, Reichard U, et al. CYP51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother 2013; 57 (8):3513-3517.
20. Tashiro M, Izumikawa K, Minematsu A, et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother 2012; 56:584-587
21. Chowdhary A, Kathuria S, Randhawa HS, et al. Isolation of multiple-triazoleresistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2012; 67:362-366. The first report of TR34/L98H in India, in clinical isolates from two azole-naive patients.
22. Seyedmousavi S, Hashemi SJ, Zibafar E, et al. Azole-resistant Aspergillus fumigatus, Iran. Emerg Infect Dis 2013; 19:832-834
23. Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47:3271-3275.
24. Rath PM, Buchheidt D, Spiess B, et al. First reported case of azole-resistant Aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob Agents Chemother 2012; 56:6060-6061
25. Hamprecht A, Buchheidt D, Vehreschild JJ, et al. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill 2012; 17:20262.
26. Mellado E, De La Camara R, Buend?́a B, et al. Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia. Rev Iberoam Micol 2013; 30:64-68
27. Tortorano AM, Venier A, Prigitano A, et al. Azole resistant Aspergillus fumigatus in the environment in Italy [abstract]. 18th Congress of the International Society for Human and Animal Mycology; 11-15 June 2012; Berlin, Germany; abstract P745.
28. Lockhart SR, Frade JP, Etienne KA, et al. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011; 55:4465-4468.
29. Chowdhary A, Kathuria S, Xu J, et al. Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR34/L98H mutations in the cyp51A gene in India. PLoS One 2012; 7:e52871
30. Badali H, Vaezi A, Haghani I, et al. Environmental study of azole-resistant Aspergillus fumigatus with TR(34) /L98H mutations in the cyp51A gene in Iran. Mycoses 2013. [Epub ahead of print]
31. Camps SM, Rijs AJ, Klaassen CH, et al. Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol 2012; 50:2674-2680
32. Vermeulen E, Maertens J, Schoemans H, Lagrou K. Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Euro Surveill 2012; 17:48.
33. European Centre for Disease Prevention and Control. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. Stockholm: ECDC 2013. http://ecdc.europa.eu/en/publications/Publications/risk-assessmentimpact- environmental-usage-of-triazoles-on-Aspergillus-spp-resistance-tomedical- triazoles.pdf [Accessed 28 May 2013]
34. Bowyer P, Denning DW. Environmental fungicides and triazole resistance in Aspergillus. Pest Manag Sci 2013. [Epub ahead of print].
35. Snelders E, Camps SM, Karawajczyk A, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 2012; 7:e31801
36. Camps SM, van der Linden JW, Li Y, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012; 56:10-16
37. Stensvold CR, Jorgenson LN, Arendrup MC. Azole-resistant invasive aspergillosis: relationship to agriculture. Curr Fungal Infect Rep 2012; 6:178-191.
38. Gemayel R, Vinces MD, Legendre M, Verstrepen KJ. Variable tandem repeats accelerate evolution of coding and regulatory sequences. Annu Rev Genet 2010; 44:445-477.
39. Fraczek MG, Bromley M, Buied A, et al. The cdr1B efflux transporter is associated with noncyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2013; 68:1486-1496
40. Camps SM, Dutilh BE, Arendrup MC, et al. Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One 2012; 7:e50034
41. Buied A, Moore CB, Denning DW, Bowyer P. High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. J Antimicrob Chemother 2013; 68:512-514
42. Paul S, Klutts JS, Moye-Rowley WS. Analysis of promoter function in Aspergillus fumigatus. Eukaryot Cell 2012; 11:1167-1177.
43. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antifungal Agents-breakpoint tables for interpretation of MICs. EUCAST 2012; version 4.1. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/ AFST/Antifungal-breakpoints-v-4.1.pdf [Accessed 4 July 2013]
44. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52:1123-1129.
45. van der Linden JW, Snelders E, Arends JP, et al. Rapid diagnosis of azoleresistant aspergillosis by direct PCR using tissue specimens. J Clin Microbiol 2010; 48:1478-1480.
46. Georgiadou SP, Kontoyiannis DP. The impact of azole resistance on aspergillosis guidelines. Ann N Y Acad Sci 2012; 1272:15-22.
47. Denning DW, Bowyer P. Voriconazole resistance in Aspergillus fumigatus: should we be concerned? Clin Infect Dis 2013; 57 (4):521-523
48. Pappas PG, Kauffman CA, Andes D, et al., Infectious Diseases Society of America.. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535.
49. Arendrup MC, Perkhofer S, Howard SJ, et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008; 52:3504-3511.
50. Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE. Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murinemodel of disseminated aspergillosis. Antimicrob Agents Chemother 2013; 57:1866-1871
51. Seyedmousavi S, Bruggemann RJ, Melchers WJ, et al. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J Antimicrob Chemother 2013; 68:385-393
52. Seyedmousavi S, Meletiadis J, Melchers WJ, et al. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother 2013; 57:796-803.
53. Seyedmousavi S, Bruggemann RJ, Melchers WJ, et al. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. Antimicrob Agents Chemother 2013; 57:303-308.
54. Jeans AR, Howard SJ, Al-Nakeeb Z, et al. Combination of voriconazole and anidulafungin for treatment of triazole-resistant Aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2012; 56:5180-5185.